

Uzbekistan

Support for Vaccine: Human Papillomavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Uzbekistan				
2. Vaccine grant number:	19-UZB-08f-Y, 1922-UZB-19b-X				
3. Date of Decision Letter:	30 September 2019				
4. Date of the Partnership Framework Agreement:	07 February 2014				
5. Programme title:	New Vaccine Support (NVS), HPV, Routine				
6. Vaccine type:	Human Papillomavirus Vaccine				
7. Requested product presentation and formulation of vaccine:	HPV Quadrivalent, 1 dose per vial, LIQUID				
8. Programme Duration:¹	2019-2022				
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)				
	2019	2020	2021	2022	Total ²
Programme Budget (US\$)	3,190,000	2,642,500	1,341,500	547,500	7,721,500
10. Vaccine introduction grant					
	Approval				
	Year	Grant Number	Amount (US\$)		
	2019	19-UZB-08f-Y	762,250		
	Disbursement				
	Disbursement date	Amount (US\$)			
	06 December, 2018	427,580			
	25 February, 2019	334,669			
11. Product switch grant:	Not applicable				
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)				
	2019	2020	2021		
Type of supplies to be purchased with Gavi funds					
Number of vaccine doses		580,500			-
Annual Amounts (US\$)	3,190,000	2,642,500			-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement:	Not applicable				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Accelerated transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022
Number of vaccine doses	250,500	330,600	508,600
Number of AD syringes	262,500	346,200	532,900
Number of re-constitution syringes	-	-	-
Number of safety boxes	2,900	3,825	5,875
Value of vaccine doses (US\$)	1,127,219	1,487,463	2,059,712
Total co-financing payments (US\$) (including freight)	1,152,500	1,521,000	2,111,000

In order to mitigate risks of stocking out in 2020, co-financing obligation associated with this program should be fulfilled by September 2020

16. Operational support for campaigns: Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019